×ðÁú¹Ù·½

English

¹ú²ú¿¹XaÖÊÁ¿ÔõÑù£¿£¿£¿£¿£¿£¿£¿£¿¶àÖÐÐÄÁÙ´²Ñо¿À´¸æËßÄ㣡

Ðû²¼ÓÚ£º2022-11-24

ÎÄÕÂȪԴ£º[ÖÐÎÄ]×ðÁú¹Ù·½ÉúÎï


µ¼Ó

2022Äê11ÔÂ13ÈÕ£¬£¬£¬£¬£¬ £¬¡°´´Ö®Éù¡±µÚÆß½ìÖйúʵÑéҽѧ´ó»á¡ª¡ª¡°ÑªË¨ÓëֹѪרÌâѧÊõÂÛ̳¡±ÔÚÏßÉÏÊ¢´ó¾ÙÐС£¡£¡£¡£¡£¡£¡£»£»£»£»£»£»£»£»áÉϾÙÐÐÁ˹ØÓÚ¿¹Xa¶àÖÐÐÄЧ¹ûµÄ»ã±¨ÓëÆÊÎö¡£¡£¡£¡£¡£¡£¡£ÄÇô¹ú²ú¿¹XaµÄÖÊÁ¿ÊÂʵÔõÑùÄØ£¿£¿£¿£¿£¿£¿£¿£¿½ÓÏÂÀ´£¬£¬£¬£¬£¬ £¬Ð¡±à½«´øÄúÈ«·½Î»ÏàʶһÏ¡£¡£¡£¡£¡£¡£¡£


ǰÑÔ£º

ÏÖÔÚ£¬£¬£¬£¬£¬ £¬¾²ÂöѪ˨˨ÈûÐÔ¼²²¡£¡£¡£¡£¡£¡£¡£¨venous thromboembolism, VTE£©ºÍ¶¯ÂöѪ˨˨ÈûÐÔ¼²²¡³ÉΪµ¼ÖÂÈ«ÇòÉú³ÝéæÃüµÄµÚһλԵ¹ÊÔ­ÓÉ¡£¡£¡£¡£¡£¡£¡£´ó´ó¶¼¾²ÂöѪ˨ÓÉÓÚûÓÐÖ¢×´Ò×±»Â©Õï¡¢ÎóÕ£¬£¬£¬£¬ £¬µ«VTEÊÇ¿ÉÒÔÔ¤·ÀµÄ£¬£¬£¬£¬£¬ £¬¿¹Äý¾ÍÊÇÔ¤·ÀºÍÖÎÁƵĻù´¡¡£¡£¡£¡£¡£¡£¡£¿ÉÊÇÔõÑù×èÖ¹¿¹ÄýÖÎÁƵ¼ÖµijöѪÐÔΣº¦£¬£¬£¬£¬£¬ £¬¡¶ÖйúѪ˨ÐÔ·ÀÖÎÖ¸ÄÏ¡·£¨2018£©¹ØÓÚ²î±ð¿¹ÄýÒ©Îï¸ø³öÁËÏà¹ØµÄ¼à²âÖ¸±ê¡£¡£¡£¡£¡£¡£¡£

  • ÈôÓ¦ÓÃUFHÖÎÁÆ£¬£¬£¬£¬£¬ £¬ÍƼöÒ»Á¬¾²Âö¸øÒ©²¢Æ¾Ö¤»î»¯²¿·ÖÄýѪøԭʱ¼ä£¨APTT£©¼à²âЧ¹ûµ÷Àí¼ÁÁ¿£¬£¬£¬£¬£¬ £¬Ö±ÖÁAPTTÑÓÉìÖÁ¿¹ÄýǰµÄ1.5~2.5±¶£¬£¬£¬£¬£¬ £¬»òµÖ´ïÏ൱ÓÚѪ½¬UFHˮƽ0.3~0.7 U/ml ʱµÄ¿¹ XaÒò×Ó£¨FXa£©»îÐÔˮƽ¡¾1C¡¿¡£¡£¡£¡£¡£¡£¡£

  • ÖðÈÕÐè´ó¼ÁÁ¿UFHÖÎÁƶøAPTT²»´ï±êʱ£¬£¬£¬£¬£¬ £¬ÍƼöͨ¹ý¼à²â¿¹FXaµÄˮƽָµ¼ÓÃÒ©¼ÁÁ¿¡¾1B¡¿¡£¡£¡£¡£¡£¡£¡£

  • Ó¦ÓÃLMWHÖÎÁƼ±ÐÔDVTʱ£¬£¬£¬£¬£¬ £¬ÈôºÏ²¢ÑÏÖØÉö¹¦Ð§²»È«£¨¼¡ôûɨ³ýÂÊ<30 ml/minʱ£¬£¬£¬£¬£¬ £¬É÷ÓÃLMWH£©£¬£¬£¬£¬£¬ £¬½¨ÒéLMWH¼õÁ¿²¢¼à²â¿¹FXa»îÐÔ¡¾2C¡¿¡£¡£¡£¡£¡£¡£¡£



¡¶¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÖÎÁÆÖйúר¼Ò¹²Ê¶£¨2015£©¡·¶ÔµÍ·Ö×Ó¸ÎËØµÄÖÎÁƹæÄ£Ò²¸ø³öÁ˽¨Ò飺ÈÑÉïʱ´úÐè°´ÆÚ¼à²â¿¹Xa»îÐÔ£¬£¬£¬£¬£¬ £¬Æä·åÖµÓ¦ÔÚ×î½üÒ»´Î×¢Éäºó4h²â¶¨£¬£¬£¬£¬£¬ £¬¹ÈÖµÓ¦ÔÚÏ´Î×¢Éäǰ²â¶¨£¬£¬£¬£¬£¬ £¬¿¹Xa»îÐÔÄ¿µÄ¹æÄ£Îª0.6¡«1.0 IU£¯ml£¬£¬£¬£¬£¬ £¬ÌìÌì¸øÒ©1´ÎµÄÄ¿µÄ¹æÄ£Îª1.0¡«2.0 IU£¯ml¡£¡£¡£¡£¡£¡£¡£

Ðí¶à»ú¹¹Ê¹Óÿ¹XaÒò×Ó»îÐԲⶨ×÷Ϊ½ð±ê×¼²âÊÔ£¬£¬£¬£¬£¬ £¬ÒÔ¼à²âºÍµ÷½âÖÎÁÆÐÔδ·Ö×é¸ÎËØºÍµÍ·Ö×Ó¸ÎËØÖÎÁƵĹÜÀí¡£¡£¡£¡£¡£¡£¡£

¡ª¡ª¡¶ELSO Anticoagulation Guideline¡·


ÏÔÉ«¿¹XaÒò×ӲⶨÊÇÏÖÔÚ¼à²âµÍ·Ö×Ó¸ÎËØºÍ»Ç´ï¸Î¿ûÄÆÖÎÁƵĽð±ê×¼¡£¡£¡£¡£¡£¡£¡£

¡ª¡ª¡¶Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux¡·



ʹÓÃUFHºÍLMWH¾ÙÐп¹ÄýÖÎÁÆÊ±£¬£¬£¬£¬£¬ £¬ÏÂÁÐÈËȺÐèÒª¾ÙÐмà²â£º

#  Ó¤Ó×¶ùºÍ¶ùͯ

#  ÀÏÈË£¨ÄêËꣾ85Ë꣩

#  ÌåÖØÒì³£Õß

#  ¼¡ôûɨ³ýÂÊÔÚ15¡«30 mL£¯minµÄÂýÐÔÉö²¡Õß

#  ÈÑÉ︾Ů

#  ÓгöѪΣº¦µÄ»¼ÕßµÈ

¿¹Xa»îÐÔ¼ì²â


¼ì²âÔ­ÀíΪ£ºÑù±¾ÖеĸÎËØÓ뿹ÄýѪøÍŽáÐγɸ´ºÏÎïºó£¬£¬£¬£¬£¬ £¬»áÓ벿·ÖXa͎ᣬ£¬£¬£¬£¬ £¬²¢Ê¹Õⲿ·ÖXaʧ»î¡£¡£¡£¡£¡£¡£¡£Ê£ÓàµÄXa¿É½«ºÏ³ÉµÄÏÔÉ«µ×ÎïÆÊÎö±¬·¢¶ÔÏõ»ù±½°·£¨PNA£©£¬£¬£¬£¬£¬ £¬PNAÔÚ405nm´¦ÓÐ×î´óÎüÊշ壬£¬£¬£¬£¬ £¬Í¨¹ý²â¶¨¶ÔÏõ»ù±½°·µÄÐγÉÁ¿À´ÅÌËã¸ÎËØ»îÐÔ¡£¡£¡£¡£¡£¡£¡£


Ê×Ò³| ×ðÁú¼¯ÍÅÖйú¹Ù·½ÍøÕ¾

¿¹Xa»îÐÔ¼ì²âÔ­Àíͼ



ÊÔ¼ÁÐÔÄÜ


×ðÁú¹Ù·½¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©Í¨¹ýÑÕɫת±äÀ´²â¶¨¿¹ÄýÇ¿¶È/ѪҩŨ¶È£¬£¬£¬£¬£¬ £¬ÏßÐÔ¿í£¬£¬£¬£¬£¬ £¬¿¹×ÌÈÅÄÜÁ¦Ç¿£¬£¬£¬£¬£¬ £¬Ï¸Ãܶȸߣ¬£¬£¬£¬£¬ £¬ÓëÊг¡Ö÷Á÷³§¼ÒÊÔ¼ÁÏà¹ØÐÔÓÅÒ죬£¬£¬£¬£¬ £¬R2£¾0.95£¬£¬£¬£¬£¬ £¬¿ÉÖª×ãÁÙ´²¼ì²âÐèÇ󡣡£¡£¡£¡£¡£¡£


Ê×Ò³| ×ðÁú¼¯ÍÅÖйú¹Ù·½ÍøÕ¾

£¨Êý¾ÝȪԴ£º¿¹Xa¶àÖÐÐÄÒ½ÔºÑù±¾±È¶ÔÊý¾Ý£©


С½á£º

¿¹Xa»îÐÔÊÔÑé¿ÉÓÃÓÚUFH¡¢LMWH¡¢»Ç´ï¸Î¹ïÄÆ¡¢Ö±½ÓFXaÒÖÖÆ¼ÁµÈ¶àÖÖÒ©ÎÄýÇ¿¶È/ѪҩŨ¶ÈµÄ²â¶¨¡£¡£¡£¡£¡£¡£¡£

4¼ÒÈý¼×Ò½ÔºÅäºÏ¼ÓÈëÁËÖйúÑо¿ÐÍҽԺѧ»áµÄ¡°¹ú²ú¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©¶àÖÐÐÄÏîÄ¿ÐÔÄÜÆÀ¼Û¡±£¨ÏîÄ¿±àºÅ£ºY2021FH-XSYZX04£©¿ÎÌ⣬£¬£¬£¬£¬ £¬¾­¶àÖÐÐÄʵÑéЧ¹ûÂÛÖ¤£º

£¨1£©¹ú²ú¿¹XaºÍ±ÈÕÕÊÔ¼ÁµÄ²âÖµµÄÏà¹ØÐÔÓÅÒ죺ÎÞÂÛÊÇͨË׸ÎËØÕվɵͷÖ×Ó¸ÎËØ£¬£¬£¬£¬£¬ £¬²âÖµÏà¹ØÐÔ¾ùÔÚR2£¾0.95£¬£¬£¬£¬£¬ £¬¿ÉÖª×ãÁÙ´²¼ì²âÐèÇ󣻣»£»£»£»£»£»£»

£¨2£©¹ú²ú¿¹XaÊÔ¼Á¿ÉÒÔÖª×ãÁÙ´²Ô¤ÆÚÓÃ;£º×ðÁú¹Ù·½¿¹XaÊÔ¼ÁºÐͨË׸ÎËØÏßÐÔ¿ÉÒÔ×öµ½4IU/mL£¬£¬£¬£¬£¬ £¬²»µ«¿ÉÒÔÖª×ã˵Ã÷ÊéËùÐû³ÆµÄ1.2IU/mL£¬£¬£¬£¬£¬ £¬Í¬Ê±¿ÉÒÔÖª×ãÁÙ´²ÉϵÄһЩÒì³£ÌØÊâ¸ßÖµÑù±¾µÄ¼ì²âÐèÇ󣻣»£»£»£»£»£»£»

£¨3£©¹ú²ú¿¹XaÊÔ¼ÁÐÔÄÜÆÀ¼ÛÓÅÒ죬£¬£¬£¬£¬ £¬ÎªÁÙ´²Ìṩ¹ú²úÌæ»»µÄÑ¡Ôñ£ºÐÔÄÜÆÀ¼ÛÊý¾ÝÏÔʾ£¬£¬£¬£¬£¬ £¬×ðÁú¹Ù·½¿¹XaÊÔ¼ÁºÐµÄ¸÷ÏîÐÔÄÜÓÈÆäÊÇÔÚ¿¹×ÌÈÅÄÜÁ¦·½Ã棬£¬£¬£¬£¬ £¬¶ÔÖ±½Óµ¨ºìËØºÍѪºìÂѰ׵Ŀ¹×ÌÈÅÄÜÁ¦ÓÅÓÚÔ­×°ÅäÌ×ÊÔ¼Á¡£¡£¡£¡£¡£¡£¡£

¿¹Xa²â¶¨ÊÔ¼ÁºÐ£¨·¢É«µ×Îï·¨£©¶©»õÐÅÏ¢


Ê×Ò³| ×ðÁú¼¯ÍÅÖйú¹Ù·½ÍøÕ¾



Ê×Ò³| ×ðÁú¼¯ÍÅÖйú¹Ù·½ÍøÕ¾



Ê×Ò³| ×ðÁú¼¯ÍÅÖйú¹Ù·½ÍøÕ¾


×¢£º±¾ÊÔ¼ÁºÐÊÊÓÃÓÚÖÖÖÖÖ÷Á÷»úÐÍ£¬£¬£¬£¬£¬ £¬»¶Ó­¸÷Ò½ÁÆ»ú¹¹¼°¾­ÏúÉÌ×Éѯ£¬£¬£¬£¬£¬ £¬ÏêÇé¿ÉÁªÏµÓÊÏ䣺sales@mdcbj.com.

¡¶¿¹Xa¶àÖÐÐÄЧ¹û»ã±¨ÓëÆÊÎö¡·

ԢĿͨµÀ


PC¶ËÊäÈëÏ·½Á´½Ó¼´¿ÉµÇ¼ÄýÑªÔÆ¿ÎÌÃÆ½Ì¨£¬£¬£¬£¬£¬ £¬Ô¢Ä¿ÊÓÆµ£º

https://vfs.xet.tech/s/2YYnDS

H5¶Ëʶ±ðÏ·½¶þάÂ룬£¬£¬£¬£¬ £¬¼´¿ÉÌø×ªÖÁÊÓÆµÒ³Ã棺

Ê×Ò³| ×ðÁú¼¯ÍÅÖйú¹Ù·½ÍøÕ¾



²Î¿¼ÎÄÏ×

[1] ÖлªÒ½Ñ§»áÒâѪ¹Ü²¡Ñ§·Ö»á·ÎѪ¹Ü²¡Ñ§×é.¼±ÐÔ·Î˨ÈûÕï¶ÏÓëÖÎÁÆÖйúר¼Ò¹²Ê¶(2015)[J].ÖлªÐÄѪ¹Ü²¡ÔÓÖ¾,2016,44(3):197-211.

[2] ÀµÓîÒ¢,Àî¹ðɺ,ÍõÖ¾Ã÷,µÈ.¿¹Xa»îÐÔ¼ì²âÔÚ¿¹ÄýÒ©Îï¼à²âÖеÄÓ¦ÓÃ[J].±ê¼ÇÃâÒ߯ÊÎöÓëÁÙ´²,2020,27(8):1444-1449.

[3] Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl): e737S-e801S.

[4] ÕźèÑÞ,Èξ²,ÃŽ£Áú.¿¹ÄýÒ©ÎïµÄʵÑéÊÒ¼à²â[J].ÖйúÐÄѪ¹ÜÔÓÖ¾,2019,24(6):565-570.

[5] Vandiver J W , Vondracek T G . Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin[J]. Pharmacotherapy, 2012, 32(6):546-558.

[6] The Extracorporeal Life Support Organization (ELSO).ELSO Anticoagulation Guideline.2014, 1-17.

[7] Babin JL, Traylor KL, Witt DM. Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux. Semin Thromb Hemost. 2017 Apr;43(3):261-269.

[8] ëøæÂ,ÀîÓÂÄÐ,Â¥ËÉ.¿¹Xa»îÐÔÔÚͨË׸ÎËØ¿¹Äý¼à²âÖÐÓ¦ÓõÄÑо¿Ï£Íû[J].ÖйúÌåÍâÑ­»·ÔÓÖ¾,2018,16(4):248-251.

[9] Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol. 2013;992:265-72. 

ÉÏÏ»¬¶¯Éó²éÍêÕû²Î¿¼ÎÄÏ×


END

ÎÄÕÂȪԴ£º×ðÁú¹Ù·½ÉúÎï  |  Ôð±à£ºEcho  |  У¶Ô£ºCassie¡¢Ð¡Ñ©



 
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿